- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Janssen Pharma launches icare4u program for skin, joint, digestive disorders
Mumbai: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the launch of icare4u, a comprehensive program to support the mental and physical health of millions of Indians affected by disorders caused by excessive inflammation.
The innovative program is being launched at a critical time, with many Indians overwhelmed by the ongoing pandemic and finding it even harder to cope with debilitating conditions that affect the skin, joints and gastrointestinal system.
Janssen India's Head of Medical Affairs, Dr. Jitendra Dixit said that conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, axial spondyloarthropathy and inflammatory bowel disease had a "huge toll" on the mental and physical health of those affected.
Research shows that people living with inflammatory disorders are at increased risk of depression and anxiety, with those most affected also experiencing worse disease activity.
"At Janssen, we are committed to improving the lives of people living with chronic immunological disorders through the provision of high-quality information and support with our new icare4u program," said Dr. Dixit.
In India, 5.2% people are living with rheumatoid arthritis, 6% suffer from axial spondyloarthropathy, up to 2.8% people live with psoriasis, of which 5 to 10% develop psoriatic arthritis, and around 16.2 per 100,000 population live with inflammatory bowel diseases such as ulterative colitiis and Crohn's disease.
Research reveals that up to four-in-ten people with rheumatoid arthritis suffer from depression and one-in-four are affected by anxiety. Half of those living with psoriatic arthritis, two thirds of those with axial spondyloarthropathy and a third of those with inflammatory bowel disease are affected by depression.
Understanding the challenges faced by patients and caregivers, the icare4u program offers support tools to help navigate the health challenges many people affected by these conditions face.
The icare4u program features a dedicated website, with comprehensive information about the diseases, videos with medical experts, and a social media community for patients and caregivers on Facebook and YouTube.
The information and support tools provided are specific to rheumatoid arthritis, axial spondyloarthropathy, psoriatic arthritis, psoriasis, ulcerative colitis and Chron's disease.
Read also: Janssen first cell therapy CARVYKTI gets USFDA nod
Janssen PharmaJohnson & JohnsonJohnson & Johnson newsicare4uexcessive inflammationrheumatoid arthritispsoriasispsoriatic arthritisaxial spondyloarthropathyinflammatory bowel diseasedepressionanxiety
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story